FI974437A - Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogeenifosforylaasi-inhibiittoreina - Google Patents

Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogeenifosforylaasi-inhibiittoreina Download PDF

Info

Publication number
FI974437A
FI974437A FI974437A FI974437A FI974437A FI 974437 A FI974437 A FI 974437A FI 974437 A FI974437 A FI 974437A FI 974437 A FI974437 A FI 974437A FI 974437 A FI974437 A FI 974437A
Authority
FI
Finland
Prior art keywords
indole
amides
carbonyl
derivatives
substituted
Prior art date
Application number
FI974437A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI974437A0 (fi
Inventor
Bernard Hulin
Dennis J Hoover
Judith L Treadway
William H Martin
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI974437A publication Critical patent/FI974437A/fi
Publication of FI974437A0 publication Critical patent/FI974437A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI974437A 1995-06-06 1997-12-05 Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogeenifosforylaasi-inhibiittoreina FI974437A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002223625A CA2223625C (en) 1995-06-06 1995-06-06 Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
PCT/IB1995/000443 WO1996039385A1 (en) 1995-06-06 1995-06-06 Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors

Publications (2)

Publication Number Publication Date
FI974437A true FI974437A (fi) 1997-12-05
FI974437A0 FI974437A0 (fi) 1997-12-05

Family

ID=25679897

Family Applications (1)

Application Number Title Priority Date Filing Date
FI974437A FI974437A0 (fi) 1995-06-06 1997-12-05 Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogeenifosforylaasi-inhibiittoreina

Country Status (40)

Country Link
US (1) US6297269B1 (ru)
EP (1) EP0832066B1 (ru)
JP (1) JP3068200B2 (ru)
CN (1) CN1374082A (ru)
AP (2) AP624A (ru)
AT (1) ATE205477T1 (ru)
AU (1) AU700887B2 (ru)
BG (1) BG62566B1 (ru)
BR (1) BR9602626A (ru)
CA (1) CA2223625C (ru)
CO (1) CO4700453A1 (ru)
CZ (1) CZ289233B6 (ru)
DE (1) DE69522718T2 (ru)
DK (1) DK0832066T3 (ru)
DZ (1) DZ2036A1 (ru)
ES (1) ES2161291T3 (ru)
FI (1) FI974437A0 (ru)
GR (1) GR3037075T3 (ru)
HR (1) HRP960266B1 (ru)
HU (1) HUP9601285A3 (ru)
IL (1) IL118236A0 (ru)
IS (1) IS1846B (ru)
LV (1) LV11614B (ru)
MA (1) MA23874A1 (ru)
MX (1) MX9709874A (ru)
NO (1) NO307335B1 (ru)
NZ (1) NZ286736A (ru)
OA (1) OA10459A (ru)
PL (1) PL314603A1 (ru)
PT (1) PT832066E (ru)
RU (1) RU2159613C2 (ru)
SG (1) SG45481A1 (ru)
SI (1) SI9600163A (ru)
SK (1) SK72096A3 (ru)
TN (1) TNSN96075A1 (ru)
TR (1) TR199600478A1 (ru)
TW (1) TW450961B (ru)
WO (1) WO1996039385A1 (ru)
YU (1) YU34796A (ru)
ZA (1) ZA964646B (ru)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297269B1 (en) * 1995-06-06 2001-10-02 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
US5952322A (en) * 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
ES2321162T3 (es) 1997-04-15 2009-06-03 Csir Compuestos y composiciones farmaceuticas que tienen actividad supresora del apetito.
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
IL133142A0 (en) * 1997-06-18 2001-03-19 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin
EP1741424B1 (en) 1997-08-11 2018-10-03 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailabilty
US6150378A (en) * 1997-10-07 2000-11-21 Cephalon, Inc. Peptidyl-containing α-ketoamide cysteine and serine protease inhibitors
US6083944A (en) * 1997-10-07 2000-07-04 Cephalon, Inc. Quinoline-containing α-ketoamide cysteine and serine protease inhibitors
US6096778A (en) 1997-10-07 2000-08-01 Cephalon, Inc. α-ketoamide multicatalytic protease inhibitors
UA57811C2 (ru) * 1997-11-21 2003-07-15 Пфайзер Продактс Інк. Композиция ингибитора альдозоредуктазы и ингибитора гликогенфосфорилазы
EP2823812A1 (en) 1998-02-02 2015-01-14 Trustees Of Tufts College Dipeptidylpeptidase IV inhibitors for use in the treatment of Type II diabetes
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
IL139203A0 (en) * 1998-05-01 2001-11-25 Lilly Co Eli Spla2 inhibitor ester
EP0978279A1 (en) * 1998-08-07 2000-02-09 Pfizer Products Inc. Inhibitors of human glycogen phosphorylase
US6686335B1 (en) 1998-09-22 2004-02-03 Cephalon, Inc. Hydroxamate-containing cysteine and serine protease inhibitors
EP1147214B1 (en) 1999-01-13 2011-01-05 The Research Foundation Of State University Of New York A novel method for designing protein kinase inhibitors
US6239163B1 (en) 1999-03-15 2001-05-29 Novo Nordisk A/S Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
US6316489B1 (en) 1999-03-15 2001-11-13 Novo Nordisk A/S Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
US6410750B1 (en) 1999-06-18 2002-06-25 Pfizer Inc. Processes and intermediates for preparing 3(S)-[(5-chloro-1H-indole-2-carbonyl)-amino]-2(R)-hydroxy-4-phenyl-butyric acid
DE60007592T2 (de) * 1999-09-30 2004-09-16 Pfizer Products Inc., Groton Bicyclische Pyrrolylamide als Glycogenphosphorylase-Inhibitoren
GB2396815B (en) 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
HUP0204278A2 (hu) 1999-11-04 2003-04-28 Ortho-Mcneil Pharmaceutical, Inc. Nem peptid szubsztituált benzotiazepinszármazékok, mint vazopresszin antagonisták, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DK1741445T3 (da) 2000-01-21 2013-11-04 Novartis Ag Kombinationer omfattende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
CA2401356A1 (en) * 2000-02-24 2001-08-30 Takeda Chemical Industries, Ltd. Combination drug
US6555569B2 (en) * 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
PE20011184A1 (es) * 2000-03-16 2001-11-15 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
US6562807B2 (en) * 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
IL144507A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
US6746856B2 (en) 2000-08-09 2004-06-08 Pfizer Inc. Microbial conversion of bicyclic heteroaromatic compounds
WO2002036066A2 (en) * 2000-11-01 2002-05-10 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising organic vanadium complexes for treatment of ischemia
US6821960B2 (en) * 2000-11-17 2004-11-23 Noyo Nordisk Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
US20030037045A1 (en) * 2001-05-21 2003-02-20 Ian Melhado Distributed computing environment for recognition of proteomics spectra
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
EP1444204A4 (en) * 2001-10-22 2009-11-04 Univ New York State Res Found INHIBITORS OF PROTEIN KINASES AND PROTEINS PHOSPHATASES, METHODS OF IDENTIFICATION AND METHODS OF USE THEREOF
CA2465382A1 (en) * 2001-10-29 2003-05-08 Japan Tobacco Inc. Indole compound and medicinal use thereof
AU2002360453C1 (en) 2001-11-26 2009-06-18 The Brigham And Women's Hospital, Inc. Methods for treating autoimmune disorders, and reagents related thereto
US7727964B2 (en) 2001-11-26 2010-06-01 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
RU2004121986A (ru) * 2002-01-18 2005-11-20 Пфайзер Продактс Инк. (Us) Промежуточные соединения для получения ингибиторов гликогенфосфорилазы
RU2278659C9 (ru) 2002-02-01 2007-02-20 Пфайзер Продактс Инк. Способ получения гомогенных, высушенных распылением твердых аморфных дисперсий лекарственного средства с использованием модифицированной установки сушки распылением
MXPA03000966A (es) * 2002-02-28 2003-09-04 Pfizer Prod Inc Agentes antidiabeticos.
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
DE10215907A1 (de) * 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10215908B4 (de) * 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
US6683106B2 (en) 2002-04-15 2004-01-27 Pfizer Inc. N-(indole-2-carbonyl)-b-alaninamide crystal forms
AU2003227360A1 (en) * 2002-04-25 2003-11-10 Yamanouchi Pharmaceutical Co., Ltd. Novel amide derivatives or salts thereof
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
DE10225635C1 (de) * 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
ATE443041T1 (de) * 2002-07-11 2009-10-15 Sanofi Aventis Deutschland Harnstoff- und urethan-substituierte acylharnstoffe, verfahren zu deren herstellung und deren verwendung als arzneimittel
UY27967A1 (es) 2002-09-10 2004-05-31 Pfizer Acetil 2-hindroxi-1,3-diaminoalcanos
JP2006507294A (ja) 2002-11-07 2006-03-02 ファイザー・プロダクツ・インク 抗糖尿病剤
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
FR2847471B1 (fr) * 2002-11-25 2006-12-29 Expanscience Lab Composition comprenant au moins un derive d'acide carbamique ,son utilisation cosmetique et comme medicament
CN1964630A (zh) 2003-02-13 2007-05-16 耶希瓦大学艾伯塔·爱恩斯坦医学院 通过控制下丘脑的长链脂肪酰基－辅酶A(LC－CoA)的水平来调控食物摄取和葡萄糖产生
US20040180845A1 (en) * 2003-03-13 2004-09-16 Newgard Christopher B. Methods and compositions for modulating glycogen synthesis and breakdown
EP1620427A1 (en) * 2003-04-17 2006-02-01 Pfizer Products Inc. Carboxamide derivatives as anti-diabetic agents
BRPI0409952A (pt) * 2003-04-30 2006-04-25 Pfizer Prod Inc agentes anti-diabéticos
US7405210B2 (en) * 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
BRPI0410445B1 (pt) * 2003-05-21 2017-11-28 Prosidion Limited Pyrrolopyridine-2-carboxylic acid amide inhibitor compound of glycogen phosphorylase, pharmaceutical composition comprising the same, process for its production and intermediate compounds
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
AR046778A1 (es) 2003-11-12 2005-12-21 Phenomix Corp Compuestos heterociclicos de acido boronico. metodos de obtencion y composiciones farmaceuticas.
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
ES2353309T3 (es) 2004-03-08 2011-03-01 Prosidion Ltd. Hidrazidas del ácido pirrolopiridin-2-carboxílico como inhibidores de glucógeno fosforilasa.
EP1768957A2 (en) * 2004-03-08 2007-04-04 Prosidion Ltd. Indole-2-carboxylic acid hydrazides as glycogen phosphorylase inhibitors
CA2573848A1 (en) 2004-07-12 2006-02-16 Phenomix Corporation Constrained cyano compounds
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055435A1 (en) * 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7214704B2 (en) 2004-11-15 2007-05-08 Bristol-Myers Squibb Company 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006059163A1 (en) * 2004-12-02 2006-06-08 Prosidion Limited Treatment of diabetes with glycogen phosphorylase inhibitors
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
CN102908350B (zh) 2005-09-14 2014-07-23 武田药品工业株式会社 用于治疗糖尿病的二肽基肽酶抑制剂
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
EP2044028B1 (en) * 2006-01-27 2012-05-16 Fibrogen, Inc. Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif)
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
DE102006042147A1 (de) * 2006-09-06 2008-03-27 Dynamit Nobel Gmbh Explosivstoff- Und Systemtechnik Hydrochloride von 3-Amino-2-hydroxycarbonsäureamiden
NZ574710A (en) 2006-09-07 2012-02-24 Nycomed Gmbh Combination treatment comprising the PDE4 inhibitor Compound A ((2R,4aR, 10bR)6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1 ,2,3,4,4a,10b-hexahydrophenanthridin-2-ol) for diabetes mellitus
SG174080A1 (en) * 2006-09-13 2011-09-29 Sanofi Aventis Isoserine derivatives for use as coagulation factor ixa inhibitors
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
US8877717B2 (en) 2007-03-12 2014-11-04 Zadec Aps Anti-diabetic extract of rooibos
EP2297114B1 (en) 2008-06-19 2018-06-06 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
SG173178A1 (en) 2009-04-03 2011-09-29 Hoffmann La Roche Propane- i-sulfonic acid {3- [5- (4 -chloro-phenyl) -1h-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
RS53176B (en) 2010-02-03 2014-06-30 Takeda Pharmaceutical Company Limited KINASE INHIBITORS 1 REGULATING SIGNALS IN APOPTOSIS
US20130072519A1 (en) 2010-05-21 2013-03-21 Edward Lee Conn 2-phenyl benzoylamides
EP2680874A2 (en) 2011-03-04 2014-01-08 Pfizer Inc Edn3-like peptides and uses thereof
CN103582630B (zh) 2011-05-31 2016-08-17 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
CA2835281A1 (en) 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
WO2012166387A1 (en) 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
MY188344A (en) 2012-03-09 2021-12-01 Biotropics Malaysia Berhad Extract formulations of rhodamnia cinerea and uses thereof
JP2016516804A (ja) 2013-04-17 2016-06-09 ファイザー・インク 心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体
CN103497181B (zh) 2013-09-30 2016-03-30 承德医学院 作为糖原磷酸化酶抑制剂的苯并氮杂卓酮类化合物、其制备方法及医药用途
US10111880B2 (en) 2013-11-05 2018-10-30 Ben-Gurion University Of The Negev Research And Development Authority Compounds for the treatment of diabetes and disease complications arising from same
MX2016011160A (es) * 2014-02-28 2017-04-27 Tensha Therapeutics Inc Tratamiento de afecciones asociadas con la hiperinsulinemia.
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
JP7128969B2 (ja) 2019-01-18 2022-08-31 アストラゼネカ・アクチエボラーグ Ｐｃｓｋ９阻害剤及びその使用方法
CN115583908B (zh) * 2021-07-05 2024-08-06 西北农林科技大学 一种吲哚甲酰胺类化合物及其制备方法和用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764610A (en) 1981-07-16 1988-08-16 E. I. Du Pont De Nemours And Company Herbicidal indole sulfonamides
US4836846A (en) 1981-07-16 1989-06-06 E. I. Du Pont De Nemours And Company Herbicidal indole sulfonamides
NZ202232A (en) 1981-11-06 1985-08-16 Smithkline Beckman Corp N-carboxyalkylproline-containing tripeptides and pharmaceutical compositions
US4933325A (en) 1985-08-14 1990-06-12 G. D. Searle & Co. Pyridyl and pyrimidinyl substituted tyrosyl dipeptide amides
US4902708A (en) 1985-12-31 1990-02-20 Biomeasure, Inc. CCK antagonists
US5089638A (en) 1986-06-16 1992-02-18 Merck & Co., Inc. Amino acid analogs as CCK-antagonists
US5034376A (en) 1986-10-31 1991-07-23 Pfizer Inc. Nor-statine and nor-cyclostatine polypeptides
HU204285B (en) 1986-10-31 1991-12-30 Pfizer Process for producing renin-inhibiting polypeptides of small molecule mass and pharmaceutical compositions containing them
EP0288965A2 (de) 1987-04-29 1988-11-02 Hoechst Aktiengesellschaft Peptide mit Phospholipase A2- hemmender Wirkung
US5128346A (en) 1987-09-21 1992-07-07 Abbott Laboratories Derivatives of D-glutamic acid and D-aspartic acid
US5250517A (en) 1987-10-06 1993-10-05 Hoffmann-La Roche Inc. Renin inhibiting compounds
WO1989010355A1 (en) 1988-04-05 1989-11-02 Abbott Laboratories Derivatives of tryptophan as cck antagonists
US5346907A (en) 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
US4904846A (en) 1988-04-29 1990-02-27 Augustin Oscadal Oil filled body heater
US5010089A (en) 1988-08-12 1991-04-23 Biomeasure, Inc. CCK antagonists and their use in treating gastrointestinal disorders
FR2643371B1 (fr) 1989-02-17 1993-11-05 Roussel Uclaf Nouveaux derives de l'acide 2-amino pentanedioique, leur procede de preparation et leur application comme medicaments
US4997950A (en) 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
IE902238A1 (en) 1989-06-30 1991-01-16 Abbott Lab Tetrapeptide type-b cck receptor ligands
IE902295A1 (en) 1989-07-07 1991-01-16 Abbott Lab Amino acid analog cck antagonists
IE66574B1 (en) 1989-12-04 1996-01-24 Searle & Co Heterocyclic acyl aminodiol beta-amino acid derivatives
DK0514442T3 (da) 1990-02-09 1994-09-26 Rhone Poulenc Rorer Sa N-Phenyl-N-acetamidoglycinamider, deres fremstilling og lægemidler med indehold deraf
EP0518961A1 (fr) 1990-03-07 1992-12-23 Aventis Pharma S.A. Derives de glycinamide, leur preparation et les medicaments les contenant
FR2674522B1 (fr) 1991-03-26 1993-07-16 Lipha Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant.
FR2678938B1 (fr) 1991-07-10 1993-10-08 Rhone Poulenc Rorer Sa Derives de pyrrolidine, leur preparation et les medicaments les contenant.
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
WO1994006755A1 (en) 1992-09-18 1994-03-31 Japan Tobacco Inc. Alcohol derivative having renin-inhibiting activity and use thereof
WO1994007815A2 (en) 1992-09-25 1994-04-14 Abbott Laboratories Small peptide anaphylatoxin receptor ligands
US6297269B1 (en) * 1995-06-06 2001-10-02 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
DE69522718T2 (de) 2002-02-07
SI9600163A (en) 1997-02-28
IS1846B (is) 2003-02-07
AU700887B2 (en) 1999-01-14
DZ2036A1 (fr) 2002-10-22
EP0832066B1 (en) 2001-09-12
TR199600478A1 (tr) 1997-03-21
IS4345A (is) 1996-12-07
CA2223625A1 (en) 1996-12-12
CN1374082A (zh) 2002-10-16
NO962322L (no) 1996-12-09
HRP960266B1 (en) 2002-08-31
NZ286736A (en) 2001-07-27
IL118236A0 (en) 1996-09-12
OA10459A (en) 2002-03-27
NO307335B1 (no) 2000-03-20
CA2223625C (en) 2003-06-03
WO1996039385A1 (en) 1996-12-12
NO962322D0 (no) 1996-06-05
BG100635A (en) 1997-09-30
CZ162796A3 (en) 1996-12-11
HRP960266A2 (en) 1997-08-31
CO4700453A1 (es) 1998-12-29
AU5475396A (en) 1996-12-19
LV11614B (en) 1997-04-20
US6297269B1 (en) 2001-10-02
PT832066E (pt) 2001-12-28
SK72096A3 (en) 1997-11-05
PL314603A1 (en) 1996-12-09
AP624A (en) 1997-12-19
LV11614A (lv) 1996-12-20
YU34796A (sh) 1999-07-28
MX9709874A (es) 1998-03-31
GR3037075T3 (en) 2002-01-31
CZ289233B6 (cs) 2001-12-12
SG45481A1 (en) 1998-01-16
ZA964646B (en) 1997-12-05
JPH11500445A (ja) 1999-01-12
AP9600816A0 (en) 1996-07-31
TNSN96075A1 (fr) 2005-03-15
TW450961B (en) 2001-08-21
AP9600817A0 (en) 1996-07-31
HU9601285D0 (en) 1996-07-29
MA23874A1 (fr) 1996-12-31
ATE205477T1 (de) 2001-09-15
JP3068200B2 (ja) 2000-07-24
FI974437A0 (fi) 1997-12-05
RU2159613C2 (ru) 2000-11-27
DK0832066T3 (da) 2001-11-19
HUP9601285A3 (en) 2001-04-28
HUP9601285A2 (hu) 1998-09-28
DE69522718D1 (en) 2001-10-18
BG62566B1 (bg) 2000-02-29
BR9602626A (pt) 1998-09-01
EP0832066A1 (en) 1998-04-01
ES2161291T3 (es) 2001-12-01

Similar Documents

Publication Publication Date Title
FI974437A0 (fi) Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogeenifosforylaasi-inhibiittoreina
DK0832065T3 (da) Substituerede N-(indol-2-carbonyl)glycinamider og derivater som glycogenphosphorylaseinhibitorer
FI961599A0 (fi) 1N-alkyyli-N-aryylipyrimidiiniamiineja ja niiden johdannaisia
DK0720609T3 (da) 3-(5-Tetrazolylbenzyl)aminoperidinderivater og antagonister for tachykininer
FI956074A0 (fi) Asetyylikolinesteraasin inhibiittoreina toimivia 1-asemasta substituoituja isatiini- ja oksindolijohdannaisia
FI991187A0 (fi) Immunoterapeuttisia imidejä/amideja PDE IV ja TNF inhibiittoreina
ATE193704T1 (de) N-(3-benzofuranyl)harnstoffderivate
NO20004277D0 (no) Indolderivater og farmasøytiske sammensetninger omfattende det samme
FI955164A (fi) Heterosykliset johdannaiset
DK0755386T3 (da) Benzamid-derivater, sammensætninger indeholdende nævnte derivat og anvendelse deraf
DE69614038D1 (de) Alkenylcyclohexanderivate und flüssigkristalline Zusammensetzungen
NO980334L (no) Anvendelse av usubstituerte og substituerte N-(pyrrol-1-yl)pyridinaminer som anti-konvulsive midler
FI933004A0 (fi) Foerfarande foer framstaellning av n-alkyl-3,4-dialkyloxianiliner och derivat daerav
ZA964409B (en) Substituted N-(indole-2-carbonyl)-glycinamides and derivatives as antidiabetic agents.
NO934473L (no) N-substituerte azabicykloheptanderivater

Legal Events

Date Code Title Description
FD Application lapsed